| Literature DB >> 29113238 |
Chuanxia Zhang1,2, Yong Qiang Wang3, Guangyi Jin4, Song Wu5, Jun Cui1,6, Rong-Fu Wang7,8,9.
Abstract
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is a rapid, reliable and widely used method of studying gene expression profiles that requires appropriate normalization for accurate and reliable results. Reference genes are usually used to normalize mRNA levels; however, the expression levels of these reference genes may vary between cell types, developmental stages, species and experimental conditions. Therefore, a normalization strategy is an important precondition for reliable conclusions, with endogenous controls requiring determination for every experimental system. In the present study, 18 reference genes used in various prior studies were analyzed to determine their applicability in bladder cancer. A total of 35 matched malignant and non-malignant bladder cancer (specifically transitional cell carcinoma) tissue specimens were examined. RNA and cDNA quality was stringently controlled. Candidate reference genes were assessed using SYBR-Green RT-qPCR. mRNA abundance was compared and reference genes with distinct ranges of expression to possible target genes were excluded. Genes that were differentially expressed in matched non-cancerous and cancerous samples were also excluded, using quantification cycle analysis. Subsequently, the stability of the selected reference genes was analyzed using three different methods: geNorm, NormFinder and BestKeeper. The rarely used ribosomal protein S23 (RPS23) was the most stable single reference gene, with RPS23, tumor protein, translationally controlled 1 and RPS13 comprising the optimal reference gene set for all the bladder samples. These stable reference genes should be employed in normalization and quantification of transcript levels in future expression studies of bladder cancer-associated genes.Entities:
Keywords: SYBR Green quantitative polymerase chain reaction; biomarker; bladder cancer; quantification cycle value; reference gene
Year: 2017 PMID: 29113238 PMCID: PMC5661485 DOI: 10.3892/ol.2017.7002
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Characteristics of transitional cell carcinoma samples.
| Characteristic | Patients, n |
|---|---|
| Total number of patients | 35 |
| Age | |
| Mean (range) | 61 (41–81) |
| Sex | |
| Male | 30 |
| Female | 5 |
| Histological grade | |
| Low | 8 |
| High | 20 |
| Unknown | 7 |
| Tumor stage[ | |
| pTa | 2 |
| pT1 | 12 |
| pT2 | 7 |
| pT3 | 6 |
| pT4 | 5 |
| Unknown | 3 |
| Lymph node status | |
| Negative | 29 |
| Positive | 3 |
| Unknown | 3 |
| Metastasis | |
| Negative | 31 |
| Positive | 1 |
| Unknown | 3 |
Tumors were staged according to tumor-node-metastasis system recommended by the American Joint Committee on Cancer (25). Each sample had matched cancerous and non-cancerous specimens.
Characteristics of 18 selected reference genes.
| Gene symbol | Gene name | GenBank accession no. | Chromosomal localization | Forward and reverse primers | Product, bp | Intron-spanning |
|---|---|---|---|---|---|---|
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | NM_002046.3 | 12p13.31 | 5′-TCTCCTCTGACTTCAACAGCGAC-3′ | ||
| 5′-CCCTGTTGCTGTAGCCAAATTC-3′ | 126 | Yes | ||||
| ACTB | β-actin | NM_001101.2 | 7p22.1 | 5′-GCCCTGAGGCACTCTTCCA-3′ | ||
| 5′-CGGATGTCCACGTCACACTTC-3′ | 100 | Yes | ||||
| ATP5B | ATP synthase, H+-transporting, mitochondrial F1 complex, β polypeptide | NM_001686.3 | 12q13.3 | 5′-TCACCCAGGCTGGTTCAGA-3′ | ||
| 5′-AGTGGCCAGGGTAGGCTGAT-3′ | 80 | Yes | ||||
| HSP90AB1 | Heat-shock protein 90 kDa alpha (cytosolic), class B member 1 | NM_001271969 | 6p12 | 5′-AAGAGAGCAAGGCAAAGTTTGAG-3′ | ||
| 5′-TGGTCACAATGCAGCAAGGT-3′ | 120 | Yes | ||||
| S100A6 | S100 calcium-A6 binding protein | NM_014624.3 | 1q21 | 5′-ACAAGCACACCCTGAGCAAGA-3′ | ||
| 5′-CCATCAGCCTTGCAATTTCA-3′ | 99 | Yes | ||||
| TMBIM6 | Transmembrane BAX inhibitor motif-containing 6 | NM_003217.2 | 12q13.12 | 5′-TGCTGGATTTGCATTCCTTACA-3′ | ||
| 5′-ACGGCGCCTGGCATAGA-3′ | 151 | Yes | ||||
| CFL1 | Cofilin 1 (non-muscle) | NM_005507.2 | 11q13 | 5′-GAAGGAGGATCTGGTGTTTATCTTCT-3′ | ||
| GCTGGCATAAATCATTTTGCTCTT-3′ | 73 | Yes | ||||
| TPT1 | Tumor protein, translationally controlled 1 | NM_001286272.1 | 13q14 | 5′-GATCGCGGACGGGTTGT-3′ | ||
| 5′-TTCAGCGGAGGCATTTCC-3′ | 100 | Yes | ||||
| UBB | Ubiquitin B | NM_018955.3 | 17p12-p11.2 | 5′-GGGCGGTTGGCTTTGTT-3′ | ||
| 5′-GACCTGTTAGCGGATACCAGGAT-3′ | 91 | Yes | ||||
| UBC | Ubiquitin C | NM_021009.6 | 12q24.3 | 5′-GATTTGGGTCGCAGTTCTT-3′ | ||
| 5′-TGCCTTGACATTCTCGATGGT-3′ | 134 | Yes | ||||
| RPS13 | Ribosomal protein S13 | NM_001017.2 | 11p15 | 5′-CGAAAGCATCTTGAGAGGAACA-3′ | ||
| 5′-TCGAGCCAAACGGTGAATC-3′ | 87 | Yes | ||||
| RPS23 | Ribosomal protein S23 | NM_001025.4 | 5q14.2 | 5′-TGGAGGTGCTTCTCATGCAA-3′ | ||
| 5′-AATGGCAGAATTTGGCTGTTTG-3′ | 76 | Yes | ||||
| SDHA | Succinate dehydrogenase complex, subunit A,flavoprotein (Fp) | NM_004168 | 5p15 | 5′-CACTGGAGGAAGCACACCC-3′ | ||
| 5′-GTCGATCACGGGTCTATATTCCAGA-3′ | 78 | Yes | ||||
| TBP | TATA box-binding protein | NM_003194.4 | 6q27 | 5′-TTCGGAGAGTTCTGGGATTGTA-3′ | ||
| 5′-TGGACTGTTCTTCACTCTTGGC-3′ | 227 | Yes | ||||
| POLR2A | Polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa | NM_000937.4 | 17p13.1 | 5′-GCACCACGTCCAATGACAT-3′ | ||
| 5′-GTGCGGCTGCTTCCATAA-3′ | 267 | Yes | ||||
| RPL13A | Ribosomal protein L13a | NM_012423 | 19q13.3 | 5′-CCTGGAGGAGAAGAGGAAAGAGA-3′ | ||
| 5′-TTGAGGACCTCTGTGTATTTGTCAA-3′ | 126 | Yes | ||||
| PPIA | Peptidyl-prolyl isomerase A (cyclophilin A) | NM_021130 | 7p13 | 5′-CCCACCGTGTTCTTCGACATT-3′ | ||
| 5′-GGACCCGTATGCTTTAGGATGA-3′ | 275 | Yes | ||||
| HPRT1 | Hypoxanthine phosphoribosyltransferase 1 | NM_000194 | Xq26.1 | 5′-GAAAAGGACCCCACGAAGTGT-3′ | ||
| 5′-AGTCAAGGGCATATCCTACAACA-3′ | 89 | Yes |
Figure 1.Primer specificity analysis for the 18 candidate reference genes. (A) Melting curves of the 18 reference genes exhibiting single peaks. (B) Agarose gel electrophoresis (1.2%) exhibited a single and specific polymerase chain reaction product of each reference gene. M, marker lane (from bottom to top: 100, 250, 500, 750, 1,000, 1,500, 2,000, 3,000 and 5,000 bp). See Table II for gene name definitions.
Quantitative polymerase chain reaction parameters providing the standard curve for each primer pair.
| Gene | Slope | Intercept | R2 | Efficiency | Dilution range |
|---|---|---|---|---|---|
| GAPDH | −3.245 | 27.050 | 0.996 | 2.03 | 1 pg-100 ng |
| ACTB | −3.221 | 28.070 | 0.999 | 2.04 | 1 pg-100 ng |
| ATP5B | −3.045 | 26.718 | 0.999 | 2.13 | 1 pg-100 ng |
| HSP90AB1 | −3.130 | 26.354 | 0.998 | 2.10 | 1 pg-100 ng |
| S100A6 | −3.252 | 28.418 | 0.999 | 2.03 | 1 pg-100 ng |
| TMBIM6 | −3.246 | 28.059 | 0.999 | 2.03 | 1 pg-100 ng |
| CFL1 | −3.151 | 27.134 | 0.999 | 2.08 | 1 pg-100 ng |
| TPT1 | −3.264 | 27.620 | 0.999 | 2.02 | 1 pg-100 ng |
| UBB | −3.359 | 27.549 | 0.999 | 1.98 | 10 pg-10 ng |
| UBC | −3.278 | 27.316 | 0.999 | 2.02 | 1 pg-100 ng |
| RPS13 | −3.288 | 28.422 | 0.999 | 2.01 | 1 pg-100 ng |
| RPS23 | −3.199 | 27.754 | 0.999 | 2.06 | 1 pg-100 ng |
| SDHA | −3.333 | 30.257 | 0.999 | 2.01 | 10 pg-10 ng |
| TBP | −3.392 | 31.279 | 0.994 | 1.97 | 10 pg-10 ng |
| POLR2A | −3.339 | 27.549 | 0.999 | 1.97 | 10 pg-10 ng |
| RPL13A | −3.067 | 27.381 | 0.998 | 2.15 | 1 pg-100 ng |
| PPIA | −3.327 | 28.560 | 0.999 | 2.00 | 1 pg-100 ng |
| HPRT1 | −3.234 | 28.451 | 0.999 | 2.05 | 10 pg-10 ng |
See Table II for gene name definitions.
Figure 2.Expression levels of the 18 candidate reference genes in the transitional cell carcinoma samples. Cq, cycle threshold. SD, standard deviation. See Table II for gene name definitions.
Figure 3.Gene expression level difference between matched non-malignant and malignant samples. The asterisks represent the mean ΔCq values [Cq (non-malignant)-Cq (malignant)]. Cq, cycle threshold. SD, standard deviation. See Table II for gene name definitions.
Figure 4.Ranking of gene stability and determination of the optimal number of reference genes evaluated using geNorm. The results are presented according to the protocol for the geNorm program output file. (A) The highest-scoring gene was gradually eliminated by calculating the average M value for all TCC samples. (B) Determination of the optimal number of reference genes for the normalization of all TCC samples. (C) The highest-scoring gene was gradually eliminated by calculating the average M value for non-malignant TCC samples. (D) Determination of the optimal number of reference genes for the normalization of non-malignant TCC samples. (E) The highest-scoring gene was gradually eliminated by calculating the average M value for malignant TCC samples. (F) Determination of the optimal number of reference genes for the normalization of malignant TCC samples. TCC, transitional cell carcinoma. See Table II for gene name definitions.
NormFinder analysis of 10 reference genes.
| Rank order | Gene name | Stability value in all samples | Gene name | Stability value in normal samples | Gene name | Stability value in cancer samples |
|---|---|---|---|---|---|---|
| 1 | UBC | 0.168 | RPS23 | 0.196 | RPS23 | 0.183 |
| 2 | UBB | 0.185 | ATP5B | 0.203 | GAPDH | 0.233 |
| 3 | TPT1 | 0.186 | TPT1 | 0.296 | ACTB | 0.249 |
| 4 | RPS23 | 0.187 | GAPDH | 0.327 | RPS13 | 0.289 |
| 5 | ATP5B | 0.194 | RPS13 | 0.339 | TPT1 | 0.290 |
| 6 | RPL13A | 0.205 | RPL13A | 0.426 | ATP5B | 0.346 |
| 7 | RPS13 | 0.207 | CFL1 | 0.592 | CFL1 | 0.374 |
| 8 | GAPDH | 0.215 | ACTB | 0.602 | RPL13A | 0.467 |
| 9 | ACTB | 0.230 | UBC | 0.628 | UBC | 0.493 |
| 10 | CFL1 | 0.241 | UBB | 0.807 | UBB | 0.745 |
BestKeeper analysis of ten candidate reference genes.
| Rank order | Gene name | R-value (P-value) in all samples | Gene name | R-value (P-value) in normal samples | Gene name | R-value (P-value) in cancer samples |
|---|---|---|---|---|---|---|
| 1 | RPS23 | 0.967 (0.01) | ATP5B | 0.973 (0.01) | TPT1 | 0.97 (0.01) |
| 2 | TPT1 | 0.964 (0.01) | RPS23 | 0.971 (0.01) | RPS23 | 0.963 (0.01) |
| 3 | ATP5B | 0.964 (0.01) | TPT1 | 0.968 (0.01) | ACTB | 0.955 (0.01) |
| 4 | UBC | 0.954 (0.01) | UBC | 0.963 (0.01) | GAPDH | 0.954 (0.01) |
| 5 | GAPDH | 0.95 (0.01) | GAPDH | 0.96 (0.01) | RPL13A | 0.948 (0.01) |
| 6 | RPS13 | 0.947 (0.01) | RPS13 | 0.95 (0.01) | RPS13 | 0.947 (0.01) |
| 7 | RPL13A | 0.942 (0.01) | ACTB | 0.939 (0.01) | ATP5B | 0.946 (0.01) |
| 8 | ACTB | 0.938 (0.01) | RPL13A | 0.933 (0.01) | UBC | 0.942 (0.01) |
| 9 | CFL1 | 0.921 (0.01) | CFL1 | 0.926 (0.01) | CFL1 | 0.921 (0.01) |
| 10 | UBB | 0.908 (0.01) | UBB | 0.92 (0.01) | UBB | 0.878 (0.01) |
The coefficient of correlation, R, demonstrates gene expression variation, which is determined by calculating the coefficient of variance and standard deviation of the Cq set. See Table II for gene name definitions.
Final ranking of 10 candidate reference genes in all transitional cell carcinoma samples.
| Rank | ΔCq | Ge Norm | Norm Finder | Best Keeper | Overall |
|---|---|---|---|---|---|
| 1 | ACTB | RPS23 | UBC | RPS23 | RPS23 |
| 2 | RPS13 | RPS13 | UBB | TPT1 | TPT1 |
| 3 | RPS23 | TPT1 | TPT1 | ATP5B | RPS13 |
| 4 | TPT1 | RPL13A | RPS23 | UBC | UBC |
| 5 | UBC | GAPDH | ATP5B | GAPDH | ACTB |
| 6 | UBB | ATP5B | RPL13A | RPS13 | ATP5B |
| 7 | ATP5B | CFL1 | RPS13 | RPL13A | UBB |
| 8 | RPL13A | ACTB | GAPDH | ACTB | RPL13A |
| 9 | CFL1 | UBC | ACTB | CFL1 | GAPDH |
| 10 | GAPDH | UBB | CFL1 | UBB | CFL1 |
Cq, cycle threshold. See Table II for gene name definitions.